Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400357 | 1.00 | CHEK1 (0.34) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6403900 | 0.90 | MMP2 (0.40) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6399506 | 0.90 | MMP2 (0.36) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6406333 | 0.90 | MMP2 (0.36) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6400972 | 0.78 | CA12 (0.35) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6399624 | 0.74 | CA2 (0.36) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6399628 | 0.74 | CA2 (0.36) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6399715 | 0.73 | MMP2 (0.39) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6400319 | 0.73 | MMP2 (0.39) | CHEK1AURKANTRK1METPIM1 | |
| SCHEMBL6397621 | 0.73 | CHEK1 (0.35) | CHEK1AURKANTRK1METPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | claimed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | claimed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | claimed |
| CN-110236198-B | Oral emulsion rich in Omega-3 unsaturated fatty acid and preparation method thereof | 宁波仙健海嘉生物科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-108048353-A | The Lactobacillus reuteri HI120 of one Expression of Plant Height linoleate isomerase LAI and its application | 广州维生君生物科技有限公司 | 2018-05-18 | — | — | CN | disclosed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| US-20050282781-A1 | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids | NATREON INC. | 2005-12-22 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-0780124-B1 | Pharmaceutical composition comprising an alkanoyl L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2001-12-19 | — | — | EP | disclosed |
| EP-0780124-A1 | Pharmaceutical composition comprising L-carnitine or an alkanoyl L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1997-06-25 | — | — | EP | disclosed |
| EP-0374188-B1 | DIETARY SUPPLEMENT UTILIZING OMEGA-3/MEDIUM CHAIN TRIGLYCERIDE MIXTURES | NEW ENGLAND DEACONESS HOSPITAL (US) | 1993-11-03 | — | — | EP | disclosed |
| EP-0188573-B1 | DIETARY SUPPLEMENT FOR MINIMIZING EFFECTS OF INFECTION | Mascioli, Edward A. (US) | 1992-03-18 | — | — | EP | disclosed |
| EP-0374188-A4 | DIETARY SUPPLEMENT UTILIZING OMEGA-3/MEDIUM CHAIN TRIGLYCERIDE MIXTURES | — | 1990-09-26 | — | — | EP | disclosed |
| EP-0374188-A1 | DIETARY SUPPLEMENT UTILIZING OMEGA-3/MEDIUM CHAIN TRIGLYCERIDE MIXTURES. | NEW ENGLAND DEACONESS HOSPITAL (US) | 1990-06-27 | — | — | EP | disclosed |
| WO-1989002275-A1 | DIETARY SUPPLEMENT UTILIZING OMEGA-3/MEDIUM CHAIN TRIGLYCERIDE MIXTURES | NEW ENGLAND DEACONESS HOSPITAL CORPORATION (US) | 1989-03-23 | — | — | WO | disclosed |
| EP-0188573-A4 | DIETARY SUPPLEMENT FOR MINIMIZING EFFECTS OF INFECTION. | NEW ENGLAND DEACONESS HOSPITAL (US) | 1987-03-30 | — | — | EP | disclosed |
| EP-0188573-A1 | DIETARY SUPPLEMENT FOR MINIMIZING EFFECTS OF INFECTION. | NEW ENGLAND DEACONESS HOSPITAL (US) | 1986-07-30 | — | — | EP | disclosed |
| WO-1986000523-A1 | DIETARY SUPPLEMENT AND METHOD OF MINIMIZING EFFECTS OF INFECTION THROUGH DIET | NEW ENGLAND DEACONESS HOSPITAL (US) | 1986-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | CHEK1 2235/4885AURKA 4645/4885NTRK1 870/4885 |
| US-20050282781-A1 | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids | ALOX15, ALOX12, BDKRB2 | CHEK1 915/4885AURKA 2414/4885NTRK1 2399/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | CHEK1 2576/4885AURKA 4704/4885NTRK1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.